Rabbit Polyclonal HLA-B Antibody

HLA-B antibodies are immunoglobulin molecules targeting epitopes on HLA-B antigens, part of the human leukocyte antigen (HLA) class I system. HLA-B molecules are critical in immune regulation, presenting endogenous peptides to CD8+ T cells for immune surveillance. Their high polymorphism (over 4.000 alleles) contributes to diverse immune responses and compatibility challenges in transplants. HLA-B antibodies typically arise from exposure to non-self HLA antigens through pregnancy, blood transfusions, or prior organ transplants. These antibodies are clinically significant in transplantation, as preformed or *de novo* antibodies can trigger hyperacute or chronic rejection by binding to donor HLA-B antigens, leading to graft injury. They are also implicated in transfusion-related acute lung injury (TRALI) and platelet refractoriness. Detection via solid-phase assays (e.g., Luminex) allows high-sensitivity identification of antibody specificity and strength. In transplant settings, HLA-B antibody screening guides donor selection to avoid antigenic mismatches. Desensitization protocols (e.g., plasmapheresis, IVIG) may mitigate antibody-mediated risks. Notably, certain HLA-B alleles (e.g., HLA-B*27) have disease associations, though their pathogenic antibodies remain less characterized. Research continues to explore epitope-based matching and tolerance induction strategies to improve outcomes in alloimmune settings.